Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetRevenue - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Cartesian Therapeutics (RNAC) Accumulated Depreciation & Amortization (2016 - 2026)

Cartesian Therapeutics (RNAC) has disclosed Accumulated Depreciation & Amortization for 12 consecutive years, with $5.3 million as the latest value for Q1 2026.

  • For Q1 2026, Accumulated Depreciation & Amortization rose 82.65% year-over-year to $5.3 million; the TTM value through Mar 2026 reached $5.3 million, up 82.65%, while the annual FY2025 figure was $4.7 million, 100.81% up from the prior year.
  • Accumulated Depreciation & Amortization hit $5.3 million in Q1 2026 for Cartesian Therapeutics, up from $4.7 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $6.3 million in Q3 2024 and bottomed at $2.4 million in Q4 2024.
  • Average Accumulated Depreciation & Amortization over 5 years is $4.9 million, with a median of $5.2 million recorded in 2022.
  • Year-over-year, Accumulated Depreciation & Amortization crashed 58.85% in 2024 and then skyrocketed 100.81% in 2025.
  • Cartesian Therapeutics' Accumulated Depreciation & Amortization stood at $5.2 million in 2022, then increased by 10.05% to $5.7 million in 2023, then plummeted by 58.85% to $2.4 million in 2024, then soared by 100.81% to $4.7 million in 2025, then increased by 12.99% to $5.3 million in 2026.
  • According to Business Quant data, Accumulated Depreciation & Amortization over the past three periods came in at $5.3 million, $4.7 million, and $4.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.